Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca will conduct the Examining Use of tiCagreLor In paD (EUCLID) study of ticagrelor to evaluate cardiovascular event rate and safety in peripheral artery disease (PAD) patients.
Subscribe to our email newsletter
The randomised, double-blind study will evaluate the efficacy of ticagrelor compared to clopidogrel in reducing the primary endpoint, a composite of CV death, MI or ischaemic stroke, in patients with PAD.
The multi-centre study, a part of the PARTHENON programme, is expected to randomise 11,500 PAD patients who are 50 years of age or older with either ticagrelor 90mg twice daily or clopidogrel 75mg once daily.
The EUCLID study principal investigator, University of Colorado School of Medicine cardiology division professor of medicine William Hiatt said the global burden of PAD is such that it necessitates further research of additional treatment options that may further reduce the risk of atherothrombotic CV events and CV death.
"The EUCLID study is an exciting clinical trial, as it may provide further clinical evidence regarding the role oral antiplatelets can play in reducing risk for patients with PAD," Hiatt added.
The study is being conducted in partnership with the Duke Clinical Research Institute, an academic research organisation affiliated with the Duke University School of Medicine, and CPC Clinical Research, an academic research organisation affiliate of the University of Colorado.
Ticagrelor is at present only approved for the prevention of cardiovascular events in patients with Acute Coronary Syndromes.